Related Experiment Videos
Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?
J F Chatal1, P Peltier, M Bardiès
1Service de Médecine Nucléaire, Site Hospitalier Nord de Nantes-St. Herblain, France.
European Journal of Nuclear Medicine
|January 1, 1992
Summary
Immunoscintigraphy shows clinical value in specific cancers and conditions, but clinician skepticism persists due to imaging limitations and unproven patient benefit. Future advancements aim to enhance diagnostic accuracy and therapeutic efficacy.
Area of Science:
- Nuclear medicine
- Oncology
- Immunotherapy
Background:
- Immunoscintigraphy has been used since 1980 for detecting cancer recurrences and non-malignant conditions.
- Clinician acceptance is limited by moderate imaging contrast, antibody immunogenicity, and lack of large-scale benefit demonstration.
Purpose of the Study:
- To review the current status and future prospects of immunoscintigraphy and radioimmunotherapy.
- To highlight challenges and potential improvements in these targeted molecular imaging and therapy techniques.
Main Methods:
- Review of clinical applications and limitations of immunoscintigraphy.
- Discussion of challenges and future directions for radioimmunotherapy, including pre-targeting strategies.
Main Results:
- Immunoscintigraphy is valuable for specific indications like colorectal and ovarian cancer recurrence detection.
- Radioimmunotherapy shows promise but requires further development in targeting, radionuclide choice, and dosimetry for broader clinical use.
Conclusions:
- Improving target-to-background ratios and reducing immunogenicity are key for immunoscintigraphy's wider adoption.
- Radioimmunotherapy advancements, particularly pre-targeting, could significantly enhance tumor-specific radiation delivery for various cancers.